Navin Fluorine International Ltd Q3 FY2024 Concall Summary

Key Takeaways

• A tough quarter, candidly owned: Revenue and profitability fell below expectations, driven by deferrals in the high-margin CDMO and specialty businesses, slower HFO plant ramp-up, and R22 pricing pressure.
• Deferrals, not destructions: Four specialty molecules slipped from Q3 to Q4, and CDMO campaigns are lumpy by nature; management expects these to be made up, with Q4 already visible as a stronger quarter.
• A capex vote of confidence: The board approved INR372 crores for a new cGMP4 CDMO facility and expanded R32 capacity, signaling conviction in medium-term demand despite current softness.
• Margins have a 3-4% one-off floor: EBITDA margin decline includes a recoupable 3-4% impact from fixed costs, deferred molecules, and HFO stabilization delays; management targets a rebound to 24%-25% as conditions improve.
• What to watch next quarter: Whether the four deferred specialty molecules actually land in Q4, any sign of HFO plant stabilization, and clarity on the CEO search conclusion.

The Quarter's Damage: What Went Wrong

• CDMO business: Revenues ran below potential because key campaigns from the last fiscal were deferred and a couple of early-phase molecules dropped out of clinical trials after data failed to meet endpoints. The business is inherently lumpy and campaign-driven.
• Specialty chemicals: Hit by a combination of customer campaign deferrals for year-end inventory reduction and the need for more work on chemical reactions. One molecule at the legacy Surat capacity faced demand challenges, though it is starting to recover.
• HFO plant ramp-up: The Dahej plant uses advanced technology with a narrow operating window. Management admitted it did not adequately account for technology absorption during ramp-up, causing delays. No structural problems exist, and the company is working closely with Honeywell to resolve them.
• R22 pricing: Continued pressure, especially in international markets, though pricing is expected to stabilize by the fiscal year-end.
• Gross margin squeeze: Standalone gross margin was also hit by the consumption of higher-priced fluorspar inventory after depleting low-price stock, an effect expected to be recouped next financial year.

Ganatra: "Unfortunately, we did not take into account as we started the ramp-up and the technology absorption. So that has taken a little more than what we would have liked to have."

CDMO: Rebranded, Reshaped, and Betting on Capacity

• Navin Molecular: The CDMO business was rebranded to sharpen its identity as the company announced a strategic U.S. partnership and an expanded MSA with a European API customer.
• cGMP4 capex: The board approved INR288 crores for Phase 1 of a new cGMP4 facility (100 KL), expected to be commissioned by end-CY25. Phase 2 will be initiated based on MSA progress. This capacity is the unlock for the directional $100 million CDMO revenue target.
• Expanded European MSA: An existing MSA covering 1 molecule was expanded to cover 2 more, totaling 3 molecules. These are intermediates to a patented commercial product and are expected to contribute materially to CDMO revenues from FY26 onward.
• U.S. partnership: A new partnership with an American CDMO player brings complementary early-stage capabilities and U.S. market access, where Navin is weaker. Navin brings fluorination and other chemistry synthesis.
• Revenue visibility: CDMO should start seeing stable revenue from commercial business, with capacities used for higher-margin early-stage products, becoming more visible in the second half of next year. Commercial-stage molecules are expected to make up 30-40% of CDMO revenue next year.
• The $100 million target: Management clarified this is directional, could be FY27 or FY28, and would not worry if it slipped by a year. The target hinges on cGMP4 coming online.

Mafatlal: "Customers today are looking at capacity. They cannot wait if the molecules are flying off. So it's our definite belief that going forward, this business has to reach the optimum levels."

Refrigerants: Playing the Transition

• R32 plant: The first phase is stabilized and operating at optimal capacity, with full utilization driven by both domestic and export demand.
• R32 expansion: INR84 crores approved for 4,500 tons of new R32 capacity, using homegrown technology. The plant is expected to be operational by February 2025. This capacity will not qualify for the Kigali subsidy but will factor into quota determination for baseline capacity.
• R32 pricing outlook: Management expects R32 pricing to follow a similar curve to R22: as quotas kick in, pricing becomes tighter and stronger. In the U.S., blending potential for R32 increases as restrictions took effect from January 1.
• R22 transition role: R22 has a unique play in the transition because it is low GWP and competitively priced compared to HFO, so blending opportunities will increase.
• HFO plant demand: Currently operating at 80% of expected capacity, with orders at the minimum level under the contract, not the higher end. Peak annual revenue of INR460 crores remains on track for FY25.

Ganatra: "It's not unfair to expect a similar pricing curve that you saw in our R22 in R32. You would expect to see something similar play out."

Specialty & Agro: Recovery Is a Second-Half Story

• Deferred molecules: Four specialty molecules deferred from Q3 are all expected to come into play by the end of Q4. A deferred purchase order, now valued at $18 million, is expected next fiscal.
• Surat campaigns: Several campaigns from last year were not repeated this fiscal but are expected to return next fiscal. The campaign-driven nature of the business causes year-on-year variation.
• Recovery trajectory: Recovery in the specialty chemicals base business is expected to be progressively better next year, but more in the second half of FY25 than the first half.
• Agro specialty plant: Chemical charge is expected by end of March/April, with first commercial supply by end of Q1 FY25. Peak revenues are expected in FY27 after a two-year ramp.
• Freesia: Full revenue of INR160 crores is expected by the end of FY24.

Margins: A One-Off Floor with a Path Back

• EBITDA margin decline: Lower sales drove lower operating leverage. Approximately 3-4% of the margin impact is attributed to one-off fixed costs, deferral of specialty molecules, and delayed HFO plant stabilization, all of which management expects to recoup.
• Other expense headwinds: Included production-related expenses, fixed costs, and timing effects like higher CSR spend this quarter versus last.
• Recovery target: As market conditions improve, management expects EBITDA margins to rebound to the 24%-25% range.

Ganatra: "Approximately 3% to 4% of the margin impact is due to one-off fixed cost, deferral of specialty molecules and delayed stabilization of HFO plant, which we expect to recoup. Further, as market conditions improve, we should start to see EBITDA margins rebound to the 24%,-25% range."

Leadership & Strategic Optionality

• CEO search: The shortlisted pool of candidates has been further evaluated, and the company hopes to conclude the process soon. Key criteria include strong industry experience, an execution excellence bias, and a solid understanding of growth drivers.
• HF capacity utilization: With new HF capacity coming up at Dahej, management is working on multiple options internally, including looking at emerging sectors, but declined to give specifics or timing.
• Refrigerant strategy: Navin will remain in the refrigerant space and play a part in the transition from high GWP to low GWP to eventually HFO. Management declined to speculate on entry into blends, saying the landscape is open depending on opportunity and capabilities.
• HFO debottlenecking: A debottlenecking project remains in the hopper but is not yet committed; discussions on doubling HFO capacity are ongoing with Honeywell at the highest levels.

Ganatra: "I'm not going to second guess that one. It would be when it would be. We are working at it, believe it, as soon as we can talk about it, we will talk about it."

Guidance & Commitments

Key Metrics